It is important to note, however, that not all patients with tumors harboring PIK3CA mutations are sensitive to PI3K pathway inhibitor treatment, and, on the other hand, that also subsets of patients with wild-type PIK3CA/PTEN cancers are responsive. The gene discussed is PIK3CA; the disease is cancer.